Why Aduhelm, a new Alzheimer's treatment, isn...

Measles is making a comeback. Ongoing outbreaks in Pennsylvania, South Carolina, Texas, and Utah have documented hundreds of cases, mostly among unvaccinated people. And while local and federal politicians debate the definitions and impact of those measles-associated deaths, heal ...  Show more

Your self-worth today can be affected by your memories. But you have power over those memories – when you re-experience them. By doing that, you can reshape your self-esteem for the better and change your perspective. That idea and the broader science of self-worth are at the hea ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more

Until recently, breakthroughs in treating Alzheimer’s disease were non-existent. But two new drugs have shown promise in moderately slowing memory and thinking problems for people with early-stage disease. While welcoming the idea of a ‘new era’ for treating Alzheimer’s disease, ...  Show more

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ...  Show more